Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0.0824 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.0824 | 0.0824 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.0824 | 0.2759 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.0824 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0035 | 0.2987 | 0.2357 |
Echinococcus multilocularis | lamin | 0.0028 | 0.1985 | 0.6645 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2987 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0028 | 0.1985 | 0.6645 |
Schistosoma mansoni | lamin | 0.0028 | 0.1985 | 0.1265 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2987 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.0824 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0028 | 0.1985 | 0.1985 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0.0824 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 1 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0035 | 0.2987 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2987 | 1 |
Brugia malayi | hypothetical protein | 0.0035 | 0.2987 | 0.2841 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2987 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0824 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.2987 | 0.2357 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.0824 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0028 | 0.1985 | 0.1818 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.0824 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0035 | 0.2987 | 1 |
Onchocerca volvulus | 0.0028 | 0.1985 | 0.5 | |
Echinococcus granulosus | lamin dm0 | 0.0028 | 0.1985 | 0.6645 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.0824 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.1985 | 0.1985 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 0.0824 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.0824 | 0.2759 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.0824 | 0.5 |
Schistosoma mansoni | lamin | 0.0028 | 0.1985 | 0.1265 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.0824 | 0.0633 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0824 | 0.5 |
Echinococcus multilocularis | musashi | 0.0028 | 0.1985 | 0.6645 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.0824 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.0824 | 0.5 |
Schistosoma mansoni | eyes absent homolog | 0.0086 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0028 | 0.1985 | 0.1985 |
Schistosoma mansoni | intermediate filament proteins | 0.0028 | 0.1985 | 0.1265 |
Echinococcus granulosus | lamin | 0.0028 | 0.1985 | 0.6645 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0015 | 0.0204 | 0.0204 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0028 | 0.1985 | 0.1818 |
Onchocerca volvulus | 0.0028 | 0.1985 | 0.5 | |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0.0824 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0028 | 0.1985 | 0.6645 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.1915 | 0.1915 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.